Are gene-by-environment interactions leveraged in multi-modality neural networks for breast cancer prediction?

Monica Isgut; Andrew Hornback; Yunan Luo; Asma Khimani; Neha Jain; May D. Wang

Home/Archive/arXiv

arXiv · 2407.20978

Are gene-by-environment interactions leveraged in multi-modality neural networks for breast cancer prediction?

Monica Isgut·Andrew Hornback·Yunan Luo·Asma Khimani·Neha Jain·May D. Wang

View original source ↗Read source document ↗Export metadata ↓

Abstract

Polygenic risk scores (PRSs) can significantly enhance breast cancer risk prediction when combined with clinical risk factor data. While many studies have explored the value-add of PRSs, little is known about the potential impact of gene-by-gene or gene-by-environment interactions towards enhancing the risk discrimination capabilities of multi-modal models combining PRSs with clinical data. In this study, we integrated data on 318 individual genotype variants along with clinical data in a neural network to explore whether gene-by-gene (i.e., between individual variants) and/or gene-by-environment (between clinical risk factors and variants) interactions could be leveraged jointly during training to improve breast cancer risk prediction performance. We benchmarked our approach against a baseline model combining traditional univariate PRSs with clinical data in a logistic regression model and ran an interpretability analysis to identify feature interactions. While our model did not demonstrate improved performance over the baseline, we discovered 248 (<1%) statistically significant gene-by-gene and gene-by-environment interactions out of the ~53.6k possible feature pairs, the most contributory of which included rs6001930 (MKL1) and rs889312 (MAP3K1), with age and menopause being the most heavily interacting non-genetic risk factors. We also modeled the significant interactions as a network of highly connected features, suggesting that potential higher-order interactions are captured by the model. Although gene-by-environment (or gene-by-gene) interactions did not enhance breast cancer risk prediction performance in neural networks, our study provides evidence that these interactions can be leveraged by these models to inform their predictions. This study represents the first application of neural networks to screen for interactions impacting breast cancer risk using real-world data.

Explore related subjects

q-bio.GN

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Monica Isgut, Andrew Hornback, Yunan Luo, Asma Khimani, Neha Jain, May D. Wang. 2024-07-30. Are gene-by-environment interactions leveraged in multi-modality neural networks for breast cancer prediction?. https://arxiv.org/abs/2407.20978

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Revolutionizing Genomics with Reinforcement Learning Techniques

In recent years, Reinforcement Learning (RL) has emerged as a powerful tool for solving a wide range of problems, including decision-making and genomics. The exponential growth of raw genomic data over the past two decades has exceeded the capacity of manual analysis, leading to a growing interest in automatic data analysis and processing. RL algorithms are capable of learning from experience with minimal human supervision, making them well-suited for genomic data analysis and interpretation. One of the key benefits of using RL is the reduced cost associated with collecting labeled training data, which is required for supervised learning. While there have been numerous studies examining the applications of Machine Learning (ML) in genomics, this survey focuses exclusively on the use of RL in various genomics research fields, including gene regulatory networks (GRNs), genome assembly, and sequence alignment. We present a comprehensive technical overview of existing studies on the application of RL in genomics, highlighting the strengths and limitations of these approaches. We then discuss potential research directions that are worthy of future exploration, including the development of more sophisticated reward functions as RL heavily depends on the accuracy of the reward function, the integration of RL with other machine learning techniques, and the application of RL to new and emerging areas in genomics research. Finally, we present our findings and conclude by summarizing the current state of the field and the future outlook for RL in genomics.

q-bio.GN↗

arXiv2026

Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only marginal improvements. Pathway-level analyses revealed sparse and inconsistent biomarker signals across models. Although scRNA-seq-based predictors converged on immune-related programs such as allograft rejection, bulk RNA-seq-based models exhibited little reproducible overlap. PRECISE and NetBio identified the most coherent immune-related themes, whereas IRNet predominantly captured metabolic pathways weakly aligned with ICI biology. Together, these findings demonstrate the limited cross-cohort robustness and biological consistency of current transcriptomic ICI prediction models, underscoring the need for improved domain adaptation, standardised preprocessing, and biologically grounded model design.

q-bio.GN↗

arXiv2026

Large Language Model Agents for Evidence Based Genetic Disease Severity Classification

Disease severity classification for genetic conditions is subjective and labor-intensive, creating bottlenecks in genomic screening, where commercial panels vary widely in size and overlap. We developed an autonomous AI agent integrating Reasoning and Acting (ReAct) with Retrieval-Augmented Generation (RAG) to classify 10,211 Human Phenotype Ontology terms. It uses American College of Medical Genetics (ACMG)-endorsed severity guidelines and American College of Obstetricians and Gynecologists (ACOG) quality-of-life criteria to retrieve PubMed literature, generate interpretable reasoning chains, and independently verify claims. At the phenotype level, using expert-curated cohorts, the agent achieved 93.55% accuracy (MCC 0.9237) with 82.6% to 91.4% of claims supported by direct evidence or valid inferences. Gene-level severity was aggregated across 8,738 pairs, identifying 3,283 autosomal recessive pairs with severe or profound presentations. External validation showed 95.2% concordance with Mackenzie's Mission gene list. This system enables standardized panel design by providing reliable, automated classification supported by direct evidence.

q-bio.GN↗